Registered title, quoted from ClinicalTrials.gov
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Shanxi Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06255704, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Histologically confirmed diagnosis of MCL according to WHO classification;
Inclusion criterion 1
Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI). Measurable disease was defined as at least 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular dimensions; in case of bone marrow infiltration only, bone marrow aspiration and biopsy are mandatory for all staging evaluations.
Inclusion criterion 7
1) Neutrophils ≥1×109/L within 7 days prior to study entry, and no growth factor support therapy.
Inclusion criterion 9
Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug
Inclusion criterion 15
ECOG, 0\~2.
Inclusion criterion 4
2) Platelets ≥75×109/L within 7 days prior to study entry without growth factor support or blood transfusion.
Inclusion criterion 10
3) Hemoglobin ≥75g/L shall not be transfused within 7 days before the test. If bone marrow is involved, neutrophils ≥0.75×109/L, platelets ≥50×109/L, hemoglobin ≥50g/L)
Inclusion criterion 11
4) Creatinine clearance ≥30ml/min
Inclusion criterion 12
5) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× upper limit of normal (ULN).
Inclusion criterion 13
Concomitant or previous malignancies within the last 2 years other than basal cell skin cancer or in situ uterine cervix cancer
Exclusion criterion 3
Patients with unresolved hepatitis B or C infection or known HIV positive infection
Exclusion criterion 10
Pregnancy or lactation
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06255704, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histologically confirmed diagnosis of MCL according to WHO classification;
- Previously untreated MCL.
- Age ≥ 18 and ≤ 70 years old.
- ECOG, 0\~2.
- Suitable for high-dose treatment including high-dose Ara-C.
- Stage II-IV (Ann Arbor).
- Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI). Measurable disease was defined as at least 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular dimensions; in case of bone marrow infiltration only, bone marrow aspiration and biopsy are mandatory for all staging evaluations.
- The following laboratory tests during the screening period (unless related to MCL disease)
- 1) Neutrophils ≥1×109/L within 7 days prior to study entry, and no growth factor support therapy.
- 2) Platelets ≥75×109/L within 7 days prior to study entry without growth factor support or blood transfusion.
- 3) Hemoglobin ≥75g/L shall not be transfused within 7 days before the test. If bone marrow is involved, neutrophils ≥0.75×109/L, platelets ≥50×109/L, hemoglobin ≥50g/L)
- 4) Creatinine clearance ≥30ml/min
- 5) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× upper limit of normal (ULN).
- International Standardized ratio (INR) ≤1.5 and activated partial prothrombin kinase time (APTT) ≤1.5×ULN. If there is a clotting factor inhibitor that causes an elevated INR or prolonged APTT, it is up to the investigator to decide whether to enroll the patient.
- Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug
- Life expectancy > 3 months.
- Written informed consent form according to GCP and national regulations.
Exclusion Criteria:
- Known CNS involvement of MCL, Leukemic non-lymphonodular mantle cell lymphoma was excluded.
- Major surgery within 4 weeks of screening
- Concomitant or previous malignancies within the last 2 years other than basal cell skin cancer or in situ uterine cervix cancer
- Clinically significant cardiovascular disease such as uncontrolled arrhythmias and hypertension , congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below 50%(AHA,2016)
- QTcF > 450 msec or other significant electrocardiogram (ECG) abnormalities including second-degree atrioventricular block Type II, or third-degree atrioventricular block
- Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of zanubrutinib itself or to the excipients in its formulation)
- Requires treatment with strong CYP3A inhibitors or strong CYP3A inducers
- Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- Active infection including infections requiring oral or intravenous antimicrobial therapy
- Patients with unresolved hepatitis B or C infection or known HIV positive infection
- History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
- Pregnancy or lactation
- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could have compromised the patient's safety, or put the study at risk
- Participation in another clinical trial within 30 days before enrollment in this study
- poor compliance
Quoted from ClinicalTrials.gov, NCT06255704, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06255704, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.